Cooper Companies Inc (COO -13.31%) shares fell roughly 13.9% as of 2:12 a.m. ET on Sept. 10, 2026, after the company's earnings report disappointed Wall Street with weak guidance and a decision to not sell CooperSurgical.
The S&P 500 and the Nasdaq Composite were both down 0.6%.
NASDAQ: COO
Key Data Points
Cooper's 2026 fourth-quarter forecasts missed Wall Street's targets
Cooper, a medical-device company, released its Q3 numbers yesterday, reporting adjusted earnings of $1.15 per share. While that beat estimates, it missed estimates on its top-line, reporting $1.07 billion in sales.
The real issue was the company's Q4 earnings forecast of $1.05 per share to $1.09 per share, which came in well below Wall Street's $1.19 estimate.
Keeping CooperSurgical removed a possible deal catalyst
Cooper's board said that after a comprehensive strategic review, the company will not sell CooperSurgical. Investors had driven up the stock price in anticipation of a deal.
Image source: Getty Images.
CooperVision pressure will continue through the fourth quarter
The company said that lower inventory at U.S. contact-lens distributors would keep hurting its 2026 numbers for the vision side of the business. The decision to keep the surgical side might help buffer earnings in the short term, but make the stock less attractive in the long term.
